marked.bio

PD-L1 ADC · ADC

HLX43

2 active trials, targeting PD-L1. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
EGFR exon 19 deletion / L858R 2 2 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of HLX43.

  1. Henlius 2

Trials

2 of 2 trials shown

  1. A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors

    Recruiting Phase 1/2 Henlius Started 2025Primary completion 2026-10 NCT06848699

    HLX43serplulimab

    … /metastatic NSCLC subjects confirmed by histology or cytology, requiring the presence of EGFR mutation and failure or intolerance to EGFR-TKI or/and platinum-based chemotherapy.

    EGFR exon 19 deletion / L858RSolid Tumor Cancer, Non Small Cell Lung Cancer

  2. A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

    Enrolling by invitation Phase 1 Henlius Started 2023Primary completion 2026-12 NCT06115642

    HLX43serplulimab

    The standard treatment for non-squamous NSCLC with known EGFR mutations is defined as EGFR inhibitors and platinum-containing chemotherapy.

    EGFR exon 19 deletion / L858RAdvanced/Metastatic Malignant Solid Tumors